Category - Markets

Markets

SVB Leerink starts Aclaris Therapeutics at OP; PT $13

SVB Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $13 price target. The stock closed at $6.34 on May 3.

May 6, 2019

Markets

HCW ups ImmunoGen to buy from neutral; PT to $7 from $3.50

H.C. Wainwright upgraded ImmunoGen (NASDAQ:IMGN) to ”buy” from “neutral” with a $7 price target, saying that a potential green light for accelerated approval sets up a compelling risk reward scenario. The stock closed...

May 6, 2019

Markets

BTIG ups Voyager Therapeutics PT to $31 from $23

BTIG raised its price target for Voyager Petroleums (NASDAQ:VYGR) to $31 from $23 after the company reported positive data from eight patients with Parkinson’s disease in a Phase 1 trial to evaluate the safety and...

May 6, 2019

Markets

Roth starts LogicBio Therapeutics at buy; PT $26

Roth Capital Partners initiated coverage of LogicBio Therapeutics (NASDAQ:LOGC) with a “buy” rating and $26 price target. The stock closed at $13.61 on April 30.

May 1, 2019

Markets

Roth starts Zynerba Pharma at buy; PT $36

Roth Capital Partners initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $36 price target. The stock closed at $11.56 on April 29

April 30, 2019

Markets

Roth starts Zafgen at buy; PT $8

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and price target of $8. The stock closed at $2.56 on April 25.

April 26, 2019

Markets

SVB Leerink starts Genfit at OP; PT $58

SVB Leerink launched coverage of French-based Genfit (NASDAQ:GNFT) with an “outperform” rating and $58 price target. The stock closed at $25.47 on April 23.

April 24, 2019